← Back to Search

Medical Food

Hepaxa for Non-alcoholic Fatty Liver Disease

N/A
Waitlist Available
Led By Reed Hogan, MD
Research Sponsored by BASF AS
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This study measures the steatosis in patients With fatty livers as determined by CAP score from a fibroscan assessment. The study attempts to determine the effect of using the Medical Food Hepaxa in a Clinical setting Close to real-world use.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The change in liver fat content (hepatic steatosis) from baseline to end of study
Secondary study objectives
Change in Level of plasma triglycerides from baseline to end of study
Change in liver function test: aspartate aminotransferase (AST) from baseline (IU/L) to end of study
Change in the liver function test: alanine aminotransferase (ALT) from baseline (IU/L) to end of study
+2 more
Other study objectives
Exploratory outcome. Stratification of effect Hepaxa using FLI score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: HepaxaExperimental Treatment1 Intervention
Subjects will receive Hepaxa according to standard use (4 capsules daily over a 6 month period)

Find a Location

Who is running the clinical trial?

BASF ASLead Sponsor
1 Previous Clinical Trials
40 Total Patients Enrolled
Reed Hogan, MDPrincipal InvestigatorGI Associates and Endoscopy Center
~7 spots leftby Nov 2025